Selected article for: "important point and International license"
Author: Craig Thompson; Nicholas Grayson; Robert Paton; José Lourenço; Bridget Penman; Lian Ni Lee; Valerie Odon; Juthathip Mongkolsapaya; Senthil Chinnakannan; Wanwisa Dejnirattisai; Matthew Edmans; Alexander Fyfe; Carol Imlach; Kreepa Kooblall; Nicholas Lim; Chang Liu; Cesar Lopez-Camacho; Carol-Anne McInally; Narayan Ramamurthy; Jeremy Ratcliff; Piyada Supasa; Beibei Wang; Alexander J Mentzer; Marc Turner; Calum Semple; John Kenneth Baillie; Heli Harvala; Gavin Screaton; Nigel Temperton; Paul Klenerman; Lisa Jarvis; Sunetra Gupta; Peter Simmonds
Title: Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure
  • Document date: 2020_4_17
    • ID: nm2bq717_30
    Snippet: The copyright holder for this preprint . https://doi.org/10.1101/2020.04.13.20060467 doi: medRxiv preprint generate antibody detectable in a commercial ELISA test 39 . Technical considerations aside, the temporal gap between exposure and seroconversion, coupled with the rapid spread of this virus means that during the initial phase of the epidemic an important difference will exist -at 340 any given time point -between the fraction of those recen.....
    Document: The copyright holder for this preprint . https://doi.org/10.1101/2020.04.13.20060467 doi: medRxiv preprint generate antibody detectable in a commercial ELISA test 39 . Technical considerations aside, the temporal gap between exposure and seroconversion, coupled with the rapid spread of this virus means that during the initial phase of the epidemic an important difference will exist -at 340 any given time point -between the fraction of those recently exposed/infected and the fraction of those who have seroconverted . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • antibody generate and international license: 1
    • cc international license and important difference: 1
    • cc international license and initial phase: 1, 2, 3, 4, 5, 6, 7
    • cc international license and international license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc international license and rapid spread: 1, 2, 3, 4, 5, 6
    • cc international license and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • epidemic initial phase and initial phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • epidemic initial phase and rapid spread: 1
    • important difference and international license: 1
    • important difference and time point: 1
    • initial phase and international license: 1, 2, 3, 4, 5, 6, 7
    • initial phase and rapid spread: 1, 2, 3, 4, 5, 6, 7, 8
    • initial phase and time point: 1, 2
    • international license and rapid spread: 1, 2, 3, 4, 5, 6, 7
    • international license and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • rapid spread and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • rapid spread and virus rapid spread: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25